Registered Office : Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.

## CONSOLIDATED

| CONSOLIDATED |  |  |  | Sr. No. | Particulars | COMPANY |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 3 Months Period ended on March 31, 2010 | es in Lacs [ exc <br> Correspondin g 3 Months Period ended on March 31, 2009 | cept for share Year to date figures for the current year ended on March 31, 2010 | data ] <br> Year to date figures for the previous year ended on March 31, 2009 |  |  | 3 Months Period ended on March 31, 2010 | es in Lacs [ ex <br> Correspondin g 3 Months Period ended on March 31, 2009 | cept for share Year to date figures for the current year ended on March 31, 2010 | data ] <br> Year to date figures for the previous year ended on March 31, 2009 |
|  |  |  |  | 1 | Sales \& Income from operations: |  |  |  |  |
| 82,597 | 71,025 | 361,423 | 291,711 | A | Gross Sales | 43,065 | 43,610 | 185,491 | 173,744 |
| 1,008 | 770 | 4,005 | 5,471 | B | Less : Excise Duty | 490 | 549 | 2,198 | 3,892 |
| 81,589 | 70,255 | 357,418 | 286,240 | C | Net Sales | 42,575 | 43,061 | 183,293 | 169,852 |
| 3,068 | 2,085 | 11,267 | 6,509 | D | Other Income from Operations | 14,602 | 5,716 | 59,196 | 24,720 |
| 84,657 | 72,340 | 368,685 | 292,749 | E | Total sales and other income from operations | 57,177 | 48,777 | 242,489 | 194,572 |
|  |  |  |  | 2 | Expenditure: |  |  |  |  |
| $(5,044)$ | ) 2,908 | $(11,334)$ | ) $(4,607)$ | A | Increase [-] / Decrease [+] in stock in trade \& work in progress | $(1,870)$ | 2,622 | $(1,080)$ | 1,792 |
| 27,952 | 15,587 | 97,889 | 66,946 | B | Consumption of materials | 20,805 | 12,075 | 70,548 | 49,836 |
| 6,151 | 5,712 | 31,280 | 33,320 | C | Purchase of traded goods | 118 | 2,542 | 7,319 | 13,350 |
| 10,821 | 7,497 | 44,059 | 35,208 | D | Employees cost | 7,526 | 4,544 | 27,790 | 21,803 |
| 3,979 | 3,140 | 13,389 | 11,182 | E | Depreciation, Amortisation \& Impairment | 2,464 | 2,286 | 9,004 | 8,256 |
| 25,842 | 25,721 | 125,924 | 101,304 | F | Other Expenditure | 15,863 | 16,650 | 76,924 | 65,763 |
| 69,701 | 60,565 | 301,207 | 243,353 | G | Total Expenditure | 44,906 | 40,719 | 190,505 | 160,800 |
| 14,956 | 11,775 | 67,478 | 49,396 | 3 | Profit from Operations before Other Income, Interest \& Exceptional Items [ 1-2] | 12,271 | 8,058 | 51,984 | 33,772 |
| 512 | 433 | 1,591 | 2,036 | 4 | Other Income | 847 | 879 | 4,351 | 5,953 |
| 15,468 | 12,208 | 69,069 | 51,432 | 5 | Profit before Interest \& Exceptional Items [ 3 + 4 ] | 13,118 | 8,937 | 56,335 | 39,725 |
| 1,575 | 4,399 | 8,092 | 9,778 | 6 A | Interest \& financial charges | 906 | 3,236 | 4,263 | 7,288 |
| 111 | $(1,290)$ | 122 | 2,270 | B | Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans | (127) | 112 | 45 | 1,514 |
| 1,686 | 3,109 | 8,214 | 12,048 | C | Total Financial cost | 779 | 3,348 | 4,308 | 8,802 |
| 13,782 | 9,099 | 60,855 | 39,384 | 7 | Profit after Interest but before Exceptional Items [ 5-6] | 12,339 | 5,589 | 52,027 | 30,923 |
| 0 | $(2,226)$ | (464) | $(2,408)$ | 8 | Exceptional Items [+] Income / [-] Expense | 0 | $(1,282)$ | 0 | $(1,282)$ |
| 13,782 | 6,873 | 60,391 | 36,976 | 9 | Profit [+] / Loss [-] from Ordinary Activities before tax [ $7+8$ ] | 12,339 | 4,307 | 52,027 | 29,641 |
| 677 | 1,582 | 7,407 | 6,658 | 10 | Tax expense | (760) | 50 | 1,700 | 3,050 |
| 13,105 | 5,291 | 52,984 | 30,318 | 11 | Net Profit [+] / Loss [-] from Ordinary Activities after tax [ 9-10 ] | 13,099 | 4,257 | 50,327 | 26,591 |
| 0 | 0 | 0 | 0 | 12 | Extraordinary items [ net of tax expense ] | 0 | 0 | 0 | 0 |
| 13,105 | 5,291 | 52,984 | 30,318 | 13 | Net Profit [+] / Loss [-] for the period [ 11-12] | 13,099 | 4,257 | 50,327 | 26,591 |
| $(1,229)$ | ) 509 | $(2,470)$ | (10) | 14 | Adjustments on consolidation [+] Income / [-] Expense | 0 | 0 | 0 | 0 |
| 11,876 | 5,800 | 50,514 | 30,308 | 15 | Net Profit [+] / Loss [-] for the period [ $13 \mathbf{+ 1 4}$ ] | 13,099 | 4,257 | 50,327 | 26,591 |
| 6,824 | 6,824 | 6,824 | 6,824 | 16 | Paid-up equity share capital [ Face Value Rs. $5 /-$ ] | 6,824 | 6,824 | 6,824 | 6,824 |
|  |  | 156,030 | 116,700 | 17 | Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year |  |  | 155,390 | 116,460 |
|  |  |  |  | 18 | Earnings Per Share [ EPS ] [ For the period - not Annualised ]: |  |  |  |  |
| 8.70 | - 4.25 | 37.01 | 22.20 | A | Basic \& Diluted EPS before \& after Extraordinary items [ Rs. ] | 9.60 | 3.12 | 36.87 | 19.48 |
| 5.80 | - 2.83 | 24.67 | 14.80 | B | Adjusted Basic \& Diluted EPS before \& after Extraordinary items [ Rs. ] | 6.40 | 2.08 | 24.58 | 12.99 |
|  |  |  |  | 19 | Public shareholding : |  |  |  |  |
| 34,406,982 | 34,629,818 | 34,406,982 | 34,629,818 |  | - Number of shares | 34,406,982 | 34,629,818 | 34,406,982 | 34,629,818 |
| 25.21\% | 25.37\% | 25.21\% | 25.37\% |  | - Percentage of Shareholding | 25.21\% | 25.37\% | 25.21\% | 25.37\% |
|  |  |  |  |  | Promoters and Promoter group Shareholding : |  |  |  |  |
|  |  |  |  | A | Pledged / Encumbered: |  |  |  |  |
| Nil | Nil | Nil | Nil |  | - Number of Shares | Nil | Nil | Nil | Nil |
| N.A. | N.A. | N.A. | N.A. |  | - Percentage of shares [ as a \% of the total shareholding of promoters and promoter group ] | N.A. | N.A. | N.A. | N.A. |
| N.A. | N.A. | N.A. | N.A. |  | - Percentage of shares [ as a \% of the total share capital of the company ] | N.A. | N.A. | N.A. | N.A. |
|  |  |  |  | B | Non-encumbered: |  |  |  |  |
| 102,092,031 | 101,869,195 | 102,092,031 | 101,869,195 |  | - Number of Shares | 102,092,031 | 101,869,195 | 102,092,031 | 101,869,195 |
| 100\% | 100\% | 100\% | 100\% |  | - Percentage of shares [ as a \% of the total shareholding of promoters and promoter group ] | 100\% | 100.00\% | 100\% | 100.00\% |
| 74.79\% | - 74.63\% | 74.79\% | 74.63\% |  | - Percentage of shares [ as a \% of the total share capital of the company ] | 74.79\% | 74.63\% | 74.79\% | 74.63\% |
| Notes: |  |  |  |  |  |  |  |  |  |
| [1] | Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website : www.zyduscadila.com and/or on the websites of BSE [ www.bseindia.com ] and/or NSE [ www.nseindia.com ]. |  |  |  |  |  |  |  |  |
| [ 2 ] | The above results for the quarter / year ended on March 31, 2010 were reviewed by the Audit Committee on April 28, 2010 and then approved by the Board of Directors at their meeting held on April 29, 2010. |  |  |  |  |  |  |  |  |
| [3] | In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited up to December 31, 2009 / February 28, 2010 and subject to limited review by their auditors for the balance period upto March 31, 2010 whereever applicable. |  |  |  |  |  |  |  |  |
| [4] | The Bonus Committee at its meeting held on April 9,2010 has allotted 68,249,507 Equity Shares of Rs. 5/- each fully paid-up as Bonus Shares in the ratio of one equity share for every two equity shares held by the members on the Record Date fixed for the purpose by capitalisation of Security Premium Account and General Reserves. Therefore the paid-up share capital of the Company is increased to 204,748,520 Equity Shares of Rs. 5/- each fully paid-up. |  |  |  |  |  |  |  |  |
| [ 5] | Zydus Animal Health Limited [ZAHL], a wholly owned subsidiary has pursuant to High Court order reduced its paid-up equity share capital from Rs. 54 |  |  |  |  |  |  |  |  |
|  | Crores to Rs. 24 Crores by cancelling 30,000,000 Equity Shares of Rs. 10/- each fully paid- up aggregating to Rs. 30 Crores. Accordingly the investment of the Company in ZAHL has been reduced to that extent. |  |  |  |  |  |  |  |  |
| [6] | The Board of Directors have recommended a dividend of Rs. 5/- per equity share [ @ 100\% ] on the increased capital of 204,748,520 equity shares (including 68,249,507 Bonus equity shares) of Rs.5/- each for the financial year ended on March 31, 2010. |  |  |  |  |  |  |  |  |
| [7] | The changes in Investments during the quarter are as under : |  |  |  |  |  |  |  |  |
|  | [ A Zydus Technologies Limited [ Additional Investment ] Rs. 5065 Lacs |  |  |  |  |  |  |  |  |
|  | [ B ] Zydus BSV Pharma Pvt. Limited [ Additional Investment ] Rs. 65 Lacs |  |  |  |  |  |  |  |  |
| [ 8 ] | The status of investor complaints : |  |  |  |  |  |  |  |  |
|  | Pending at the beginning of the quarter - Nil, received during the quarter - 21 , disposed off during the quarter - 20 , pending at the end of the quarter - 1 .The Company has one segment of activity viz., "Pharmaceuticals". |  |  |  |  |  |  |  |  |
| [ 9 ] |  |  |  |  |  |  |  |  |  |  |  |

